Skip to Content

Bioscience - Articles

September 17, 2019

Navrogen raises $3.2M in funding

Navrogen Inc. has raised $3.2M in convertible note financing to support its operations, Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities....

By Adam Burroughs

September 13, 2019

Castle Creek to buy Fibrocell Science

With the resources of CCP Holdings' subsidiary, Castle Creek Pharmaceuticals LLC, Fibrocell's gene therapy platform can be advanced into additional areas of high, unmet need with the potential to develop multiple, promising new therapies....

By Adam Burroughs

September 9, 2019

SequenceBase bought by Clarivate Analytics

SequenceBase is being acquired by Clarivate Analytics in a move expected to deliver an expanded solution to the fast-growing biologics market....

By Adam Burroughs

September 4, 2019

Passage Bio closes $110M Series B round

Passage Bio has closed a $110.0 million Series B financing....

By Adam Burroughs

September 3, 2019

Gyroscope Therapeutics raises $62M Series B round

Gyroscope Therapeutics, headquartered in Ambler, has raised a $62.2 million (£50.4 million) Series B financing round....

By Adam Burroughs

September 3, 2019

Roche extends Spark offer (yes, again) giving more time for regulatory approval

Roche has again extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of common stock of Spark Therapeutics Inc. for $114.50 per share....

By Adam Burroughs

August 8, 2019

Keystone Biologicals bought by BioIVT

Keystone Biologicals Inc., a supplier of disease-state plasma, sera and controls, located in Hatboro, Pennsylvania, has been acquired by BioIVT in a deal expected to expand BioIVT's disease-state portfolio both by volume and product range....

By Adam Burroughs

July 24, 2019

Pennsylvania Biotechnology Center launches Hatch BioFund Management investment arm

The Pennsylvania Biotechnology Center, a life science incubator, launched its Hatch BioFund Management LLC, a $50 million internal investment arm meant to support its early-stage companies....

By Adam Burroughs

July 16, 2019

Convelo Therapeutics agreement with Genentech opens door to acquisition

Convelo Therapeutics Inc., a Cleveland-based biotechnology company, has entered into an exclusive worldwide collaboration with Genentech, a member of the Roche Group. Through the deal, Genentech retains an exclusive option to acquire Convelo....

By Adam Burroughs

July 11, 2019

Orchestra BioMed completes $34M Series B-1 preferred stock financing round

New Hope-based Orchestra BioMed Inc., a biomedical innovation company working in procedure-based medicine, has completed a $34 million Series B-1 preferred stock financing....

By Adam Burroughs

July 8, 2019

Spark, Roche deal put on hold

Spark Therapeutics’ acquisition by Roche has been put on hold as the two companies agreed to extend the deadline for the Swiss drugmaker’s $4.3 billion takeover bid for the U.S. gene therapy specialist, according to Reuters. The report noted that Roche remains committed to a deal....

By Adam Burroughs

July 1, 2019

Century Therapeutics gets $250M in funding

The funding from Bayer, Versant and Fujifilm Cellular Dynamics will allow Century to move multiple programs into clinical development for hematologic and solid malignancies....

By Adam Burroughs

April 12, 2019

NEO bioscience companies landed $294M in 2018

Dealmaking is hot in Northeast Ohio’s biomedical community, with 71 regional companies receiving $294 million in funding in 2018. BioEnterprise’s Aram Nerpouni explains how this dealmaking trend could become the “new normal.”...

By Mark Scott